



Life Sciences

2014: Recognized both globally and nationally as a leading life sciences practice, WilmerHale has four decades of experience representing biotechnology, pharmaceutical and medical device companies at all stages of growth, as well as venture capitalists and investment banks. We have represented life sciences clients in venture financings, public offerings, mergers and acquisitions, and strategic alliances and collaborations; protected their innovations through patent prosecution and portfolio development; defended their interests in enterprise-critical patent litigation; and navigated regulatory issues vital to their success. The following is a selection of our recent life sciences transactions.

Counsel of Choice to Life Sciences Innovators

SERVING INDUSTRY LEADERS IN BIOTECHNOLOGY, PHARMACEUTICALS, MEDICAL DEVICES AND BEYOND



Mergers and Acquisitions/Strategic Alliances and Collaborations

 Acquisition of Rempex Pharmaceuticals \$474,000,000 (including milestone payments) December 2013	 Mitochondria-related disease collaboration and acquisition option with Astellas	 Acquisition by Cynosure \$294,000,000 June 2013	 Antibody discovery platform licenses with GlaxoSmithKline, Biogen Idec and Novo Nordisk	
 Diagnostic collaboration with Pacific Biosciences	 Ophthalmic collaboration with Portola Pharmaceuticals	 Sale of cell culture, gene modulation and magnetic beads businesses to GE Healthcare \$1,065,000,000 March 2014	 Licensing, clinical trial and manufacturing agreements	 Royalty financing transaction with Novo A/S

Initial Public Offerings

 Initial Public Offering of Common Shares \$91,800,000 Counsel to Issuer February 2014	 Initial Public Offering of Common Stock \$88,700,000 Counsel to Issuer June 2013	 Initial Public Offering of Common Stock \$192,280,000 Counsel to Issuer September 2013	 Initial Public Offering of Common Stock \$93,100,000 Counsel to Issuer February 2014	
 Initial Public Offering of Common Stock \$75,000,000 Counsel to Issuer March 2013	 Initial Public Offering of Common Stock \$144,417,000 Counsel to Issuer June 2013	 Initial Public Offering of Common Stock \$92,000,000 Counsel to Underwriters October 2013	 Initial Public Offering of Common Stock \$121,900,000 Counsel to Issuer July 2013	 Initial Public Offering of Common Stock \$125,120,000 Counsel to Issuer December 2013

Venture Capital Financings

 \$34,200,000 First Round December 2013	 \$50,000,000 (total committed amount) First Round October 2013	 \$30,000,000 Fifth Round November 2013	 \$26,000,000 First Round March 2013	 \$43,000,000 First Round November 2013
 \$35,500,000 Fifth Round May 2013	 \$45,000,000 First Round October 2013	 \$32,400,000 Second Round October 2013	 \$30,000,000 First Round April 2013	

Follow-on Offerings

 Public Offering of Convertible Senior Notes \$125,000,000 Counsel to Issuer July 2013	 Public Offering of Common Stock \$57,558,000 Counsel to Issuer April 2013	 Public Offering of Common Stock \$57,503,000 Counsel to Issuer January 2013	 Public Offering of Common Stock \$141,913,000 Counsel to Issuer February 2013	 Public Offering of Common Stock \$107,000,000 Counsel to Issuer February 2014
 Public Offering of Senior Notes \$3,200,000,000 Counsel to Issuer December 2013	 Public Offering of Common Stock \$456,663,000 Counsel to Issuer April 2013	 Rule 144A Placement of Convertible Senior Notes \$120,000,000 Counsel to Issuer January 2013	 Public Offering of Common Stock \$201,250,000 Counsel to Issuer August 2013	



Mixed Sources
Product group from well-managed
forests, controlled sources and
recycled wood or fiber
www.fsc.org Cert no. BV-COC-070904
© 1996 Forest Stewardship Council

14_0281 KW 4/14 3000

WilmerHale recognizes its corporate responsibility to environmental stewardship.

wilmerhale.com

Wilmer Cutler Pickering Hale and Dorr LLP is a Delaware limited liability partnership. WilmerHale principal law offices: 60 State Street, Boston, Massachusetts 02109, +1 617 526 6000; 1875 Pennsylvania Avenue, NW, Washington, DC 20006, +1 202 663 6000. Our United Kingdom offices are operated under a separate Delaware limited liability partnership of solicitors and registered foreign lawyers authorized and regulated by the Solicitors Regulation Authority (SRA No. 287488). Our professional rules can be found at www.sra.org.uk/solicitors/code-of-conduct.page. A list of partners and their professional qualifications is available for inspection at our UK offices. In Beijing, we are registered to operate as a Foreign Law Firm Representative Office. This material is for general informational purposes only and does not represent our advice as to any particular set of facts; nor does it represent any undertaking to keep recipients advised of all legal developments. Prior results do not guarantee a similar outcome. © 2014 Wilmer Cutler Pickering Hale and Dorr LLP